Article

Nine major pharmaceutical companies, including Amgen and Merck, have agreed to Most Favored Nation pricing as part of an initiative from the Trump administration aimed at reducing prescription drug costs, affecting Medicare, Medicaid, and uninsured patients. This pricing model, set to take effect in January 2026, is projected to save approximately $12 billion annually and will lead to significant price reductions for drugs like Plavix and insulin. Additionally, the agreements include over $150 billion in U.S. manufacturing investments.